An in vitro investigation of the effects of the nerve agent pretreatment pyridostigmine bromide on human peripheral blood T-cell function

International Immunopharmacology
Gary TelfordG D Griffiths

Abstract

The current pretreatment against nerve agent poisoning deployed by the UK and US armed forces is the acetylcholinesterase (EC 3.1.1.7) inhibitor pyridostigmine bromide (PB). At higher doses, PB is also used to treat the autoimmune disease myasthenia gravis. In both cases, the therapeutic effect is mediated by inhibition of acetylcholinesterase (AChE) at cholinergic synapses. However, the location of AChE is not restricted to these sites. AChE, acetylcholine (ACh) receptors and choline acetyltransferase have been reported to be expressed by T cells, suggesting that cholinergic signalling may exert some modulatory influence on T-cell function and consequently on the immune system. The aim of this study was to investigate the role of the T-cell cholinergic system in the immunological activation process and to examine whether inhibitors of AChE such as PB affect immune function. To investigate this, human peripheral blood mononuclear cells (PBMC) were stimulated using either mitogen, cross-linking of the T-cell receptor and co-receptors with antibodies (anti-CD3/CD28) or by antigen presentation in the presence of various AChE inhibitors and ACh receptor agonists or antagonist. Several indices were used to assess T-cell activation, ...Continue Reading

References

Jul 1, 1992·International Journal of Immunopharmacology·D FlipoM Fournier
Mar 15, 1989·Toxicology and Applied Pharmacology·P O Ogunbiyi, H P Misra
Nov 27, 1987·Journal of Chromatography·H MatsunagaK Oda
Oct 1, 1987·Immunology Letters·J SzelényiS Hollán
Dec 1, 1986·Environmental Research·M C FioreD Belluck
Feb 1, 1982·British Journal of Haematology·J G SzelényiS R Hollán
Jan 1, 1995·Immunology Letters·I RinnerK Schauenstein
Apr 26, 1996·Neuroscience Letters·E BronzettiA Ricci
Apr 29, 1998·Immunological Reviews·C Morimoto, S F Schlossman
Mar 19, 1999·Clinical and Experimental Pharmacology & Physiology·I WesslerK Racké
May 18, 1999·Biochemical and Biophysical Research Communications·G Johnson, S W Moore
Apr 13, 2000·Pharmacology & Therapeutics·K Kawashima, T Fujii
Dec 29, 2000·Drugs·L J Scott, K L Goa
Mar 13, 2001·Japanese Journal of Pharmacology·T Fujii, K Kawashima
Jun 14, 2001·Lancet·J Parkin, B Cohen
Oct 11, 2001·Proceedings of the National Academy of Sciences of the United States of America·T IshiiC Morimoto
Jul 1, 1961·Biochemical Pharmacology·G L ELLMANR M FEATHER-STONE
Sep 23, 2003·Molecular Pharmacology·Marina V SkokRégis Grailhe

❮ Previous
Next ❯

Citations

Aug 2, 2006·Autonomic & Autacoid Pharmacology·R M Eglen
Jun 19, 2012·Experimental Physiology·Marcus Paulo Ribeiro MachadoValdo Jose Dias da Silva
Jun 23, 2010·Journal of Clinical Apheresis·Zbigniew M SzczepiorkowskiUNKNOWN Apheresis Applications Committee of the American Society for Apheresis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.